Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

被引：0
作者：
Georg Auzinger
E. Geoffrey Playford
Christopher N. Graham
Hediyyih N. Knox
David Weinstein
Michal Kantecki
Haran Schlamm
Claudie Charbonneau
机构：
[1] King’s College Hospital,
[2] Princess Alexandra Hospital,undefined
[3] RTI Health Solutions,undefined
[4] Research Triangle Park,undefined
[5] Pfizer International Operations,undefined
[6] Pfizer Inc,undefined
来源：
BMC Infectious Diseases | / 15卷
关键词：
Anidulafungin; Candidaemia; Echinocandin; Invasive Candidiasis; Cost-Effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache
    Morris, James
    Straube, Andreas
    Diener, Hans-Christoph
    Ahmed, Fayyaz
    Silver, Nicholas
    Walker, Simon
    Liebler, Eric
    Gaul, Charly
    JOURNAL OF HEADACHE AND PAIN, 2016, 17
  • [42] Bayesian cost-effectiveness analysis with two measures of effectiveness:: the cost-effectiveness acceptability plane
    Negrín, MA
    Vázquez-Polo, FJ
    HEALTH ECONOMICS, 2006, 15 (04) : 363 - 372
  • [43] Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
    Harrington, Rachel
    Lee, Edward
    Yang, Hongbo
    Wei, Jin
    Messali, Andrew
    Azie, Nkechi
    Wu, Eric Q.
    Spalding, James
    ADVANCES IN THERAPY, 2017, 34 (01) : 207 - 220
  • [44] Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
    Vazquez, Jose
    Reboli, Annette C.
    Pappas, Peter G.
    Patterson, Thomas F.
    Reinhardt, John
    Chin-Hong, Peter
    Tobin, Ellis
    Kett, Daniel H.
    Biswas, Pinaki
    Swanson, Robert
    BMC INFECTIOUS DISEASES, 2014, 14
  • [45] Cost-effectiveness analysis in radiology
    Singer, ME
    Applegate, KE
    RADIOLOGY, 2001, 219 (03) : 611 - 620
  • [46] The Limits of Cost-Effectiveness Analysis
    Weintraub, William S.
    Cohen, David J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (01) : 55 - 58
  • [47] Cost-effectiveness analysis in oncology
    Earle, CC
    Coyle, D
    Evans, WK
    ANNALS OF ONCOLOGY, 1998, 9 (05) : 475 - 482
  • [48] Cost-effectiveness analysis and innovation
    Jena, Anupam B.
    Philipson, Tomas J.
    JOURNAL OF HEALTH ECONOMICS, 2008, 27 (05) : 1224 - 1236
  • [49] Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
    Purmonen, Timo
    Puolakka, Kari
    Mishra, Dinesh
    Gunda, Praveen
    Martikainen, Janne
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 159 - 168
  • [50] Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
    Jose Vazquez
    Annette C Reboli
    Peter G Pappas
    Thomas F Patterson
    John Reinhardt
    Peter Chin-Hong
    Ellis Tobin
    Daniel H Kett
    Pinaki Biswas
    Robert Swanson
    BMC Infectious Diseases, 14
12345